| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | IL-31 |
| WB Predicted band size | 18 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL31 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于IL-31抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Anti-Interleukin-31 Receptor Antibodies for Atopic Dermatitis*
**作者**：Ruzicka T, et al.
**摘要**：该研究报道了抗IL-31受体α单抗(Nemolizumab)在特应性皮炎患者中的III期临床试验结果，显示抗体显著减轻瘙痒症状并改善皮肤炎症，表明靶向IL-31信号通路是治疗瘙痒相关皮肤疾病的有效策略。
2. **文献名称**：*IL-31 and Its Receptor Contribute to Cutaneous Inflammation and Fibrosis in a Murine Model*
**作者**：Furue M, et al.
**摘要**：通过小鼠模型研究IL-31及其受体在皮肤炎症和纤维化中的作用，发现阻断IL-31信号可减少Th2型炎症反应和胶原沉积，提示IL-31抗体在治疗慢性皮肤病中的潜在应用。
3. **文献名称**：*Therapeutic Targeting of IL-31 in Pruritic Diseases: A Humanized Antibody Approach*
**作者**：Singh B, et al.
**摘要**：研究开发了一种人源化抗IL-31抗体，并在动物模型中验证其缓解实验性皮炎和慢性瘙痒的效果，证明其通过抑制IL-31与受体结合发挥治疗作用。
---
以上文献均聚焦于IL-31抗体在瘙痒、炎症及纤维化中的机制与临床转化，涵盖临床试验、动物模型及分子机制研究。如需具体期刊信息或年份，可进一步补充。
Interleukin-31 (IL-31) is a cytokine primarily produced by activated T cells, particularly Th2 cells, and is implicated in pruritus (itching) and inflammatory skin diseases. It signals through a receptor complex composed of IL-31 receptor alpha (IL-31RA) and oncostatin M receptor beta (OSMRβ), activating pathways like JAK/STAT, which drive inflammation and sensory nerve stimulation. Dysregulated IL-31 expression is linked to chronic pruritic conditions, including atopic dermatitis (AD), allergic contact dermatitis, and prurigo nodularis.
IL-31-targeting antibodies, such as anti-IL-31 or anti-IL-31RA monoclonal antibodies, aim to neutralize IL-31 signaling to alleviate itching and skin inflammation. For example, nemolizumab, an anti-IL-31RA antibody, has shown efficacy in clinical trials for AD, significantly reducing pruritus and lesion severity. These therapies offer a targeted approach compared to broad immunosuppressants, potentially minimizing systemic side effects. Research continues to explore their long-term safety, broader applications in eosinophilic disorders, and combination strategies with other biologics. IL-31 antibodies represent a promising frontier in managing chronic pruritic diseases, addressing both symptoms and underlying inflammation.
×
